Article
Medicine, Research & Experimental
Yixin Ren, Xiaoyun Li, Cong Chen
Summary: Master protocols, such as umbrella trials and platform trials, can save patient resources, increase trial efficiency, and reduce drug development costs when evaluating multiple experimental treatments with a common control. Umbrella trials, which evaluate two experimental arms with a common control and allow the addition of a second experimental arm later, are more practical for individual companies compared to phase 3 platform trials. Limited research has been done on statistical properties and guidance of these types of trials, and this article aims to provide statistical considerations and practical guidance for the implementation by individual companies.
CONTEMPORARY CLINICAL TRIALS
(2021)
Article
Health Care Sciences & Services
Ian C. Marschner, Manjula Schou, Andrew J. Martin
Summary: This paper addresses the issue of clinical trials stopping early for benefit and proposes a penalised maximum likelihood estimate as a supplementary analysis. The method shows good properties and efficiency when the trial is stopped early for benefit.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2022)
Article
Mathematical & Computational Biology
Lauren Kanapka, Anastasia Ivanova
Summary: This article discusses a multi-arm trial design with multiple active treatments and a control group. By assuming a certain order for the treatment effects, the objective is to compare each active treatment to the control group while maintaining control of the type 1 error rate. The results show that using the order of treatment effects to calculate the test statistic and set the testing order can reduce the sample size by at least 20% compared to testing each active treatment against the control independently.
STATISTICS IN MEDICINE
(2023)
Article
Mathematical & Computational Biology
Alessandra Serra, Pavel Mozgunov, Thomas Jaki
Summary: Multi-arm multi-stage (MAMS) designs can improve efficiency by studying multiple treatment arms concurrently, dropping poorly performing arms early, and incorporating the order of treatment effects without assuming parametric models. The design efficiently identifies promising treatments with strong control of the family-wise error rate. By including ordering information, it leads to better decision-making compared to fixed sample and conventional MAMS designs, achieving reductions in sample size of around 15% in considered settings.
STATISTICS IN MEDICINE
(2022)
Article
Clinical Neurology
Tom Foltynie, Sonia Gandhi, Cristina Gonzalez-Robles, Marie-Louise Zeissler, Georgia Mills, Roger Barker, James Carpenter, Anette Schrag, Anthony Schapira, Oliver Bandmann, Stephen Mullin, Joy Duffen, Kevin McFarthing, Jeremy Chataway, Mahesh Parmar, Camille Carroll
Summary: Multi-arm, multi-stage platform designs have improved the efficiency of clinical trials in the field of oncology. Foltynie et al. discuss the challenges and considerations of using this approach to assess potential disease-modifying treatments in progressive neurological conditions such as Parkinson's disease.
Article
Mathematical & Computational Biology
Jianrong Wu, Yimei Li, Liang Zhu
Summary: A multi-arm trial allows simultaneous comparison of multiple experimental treatments with a common control, improving efficiency compared to traditional randomized controlled trials. This paper presents a group sequential multi-arm multi-stage (MAMS) trial design based on the sequential conditional probability ratio test, providing analytical solutions for futility and efficacy boundaries for an arbitrary number of stages and arms.
STATISTICS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Charis Wong, Rachel S. Dakin, Jill Williamson, Judith Newton, Michelle Steven, Shuna Colville, Maria Stavrou, Jenna M. Gregory, Elizabeth Elliott, Arpan R. Mehta, Jeremy Chataway, Robert J. Swingler, Richard Anthony Parker, Christopher J. Weir, Nigel Stallard, Mahesh K. B. Parmar, Malcolm R. Macleod, Suvankar Pal, Siddharthan Chandran
Summary: MND-SMART is a multi-arm, multi-stage, adaptive trial aimed at efficiently evaluating the efficacy of drugs. The trial design reduces time, cost, and participant numbers, while minimizing the risk of participants receiving ineffective treatments.
Article
Mathematical & Computational Biology
Alessandra Serra, Pavel Mozgunov, Thomas Jaki
Summary: This study proposes a Bayesian multi-arm multi-stage trial design that efficiently selects promising treatments and incorporates information about the order in treatment effects and prior knowledge. The design allows for uncertainty in treatment effect order assumption and does not assume any parametric arm-response model.
STATISTICS IN MEDICINE
(2023)
Article
Dermatology
Matthew A. Popplewell, Brenig L. Gwilym, Ruth A. Benson, Maciej Juszczak, David Bosanquet, Thomas D. Pinkney, Ian Chetter, Michael Wall
Summary: A survey was conducted among vascular clinicians to assess their opinion and practice on interventions to prevent groin wound surgical site infection (SSI) following arterial surgery. The majority of participants believed that groin wound SSI is a major problem and expressed willingness to use the proposed interventions. There was clinical equipoise in randomizing patients to any of the interventions versus standard care, although some reluctance was observed regarding the use of impregnated incise drapes.
INTERNATIONAL WOUND JOURNAL
(2023)
Article
Multidisciplinary Sciences
Caroline S. Clarke, Rachael M. Hunter, Andrea Gabrio, Christopher D. Brawley, Fiona C. Ingleby, David P. Dearnaley, David Matheson, Gerhardt Attard, Hannah L. Rush, Rob J. Jones, William Cross, Chris Parker, J. Martin Russell, Robin Millman, Silke Gillessen, Zafar Malik, Jason F. Lester, James Wylie, Noel W. Clarke, Mahesh K. B. Parmar, Matthew R. Sydes, Nicholas D. James
Summary: Adding abiraterone acetate and prednisolone to standard of care improves survival in advanced prostate cancer patients. The cost-effectiveness of providing abiraterone acetate in the English National Health Service was evaluated. The results showed that abiraterone acetate is effective for both non-metastatic and metastatic disease but is not cost-effective when using the standard price.
Article
Medicine, Research & Experimental
Dena R. Howard, Anna Hockaday, Julia M. Brown, Walter M. Gregory, Susan Todd, Tahla Munir, Jamie B. Oughton, Claire Dimbleby, Peter Hillmen
Summary: The FLAIR trial successfully incorporated an emerging experimental therapy through amendments, reducing the time to reach primary outcomes. Changes to protocol and randomisation were seamless, with approval from oversight committees and partners. This strategy allowed for early assessment within a confirmatory trial, demonstrating feasibility and benefits for patients and the research community.
Article
Nutrition & Dietetics
Franziska Grundler, Magalie Viallon, Robin Mesnage, Massimiliano Ruscica, Clemens von Schacky, Frank Madeo, Sebastian J. J. Hofer, Sarah J. J. Mitchell, Pierre Croisille, Francoise Wilhelmi de Toledo
Summary: Fasting-induced changes in metabolic and signaling pathways have been found to contribute to longer and healthier lifespans in animal models. However, the role of different tissues and organs in fueling fasting metabolism is not fully understood, and the changes in organ volume and composition during fasting and food reintroduction remain relatively unexplored. This study aims to investigate the effects of long-term fasting and food reintroduction in humans through a multi-systemic approach, focusing on changes in body composition, organ and tissue volume, lipid transport and storage, protein utilization, blood metabolites, and gut microbiome profiles. State-of-the-art techniques, such as magnetic resonance imaging and spectroscopy, will be used to examine the quantitative changes in organ volume and function. The results of this study will be disseminated through peer-reviewed publications, international conferences, and social media.
FRONTIERS IN NUTRITION
(2022)
Review
Medicine, Research & Experimental
Elias Laurin Meyer, Peter Mesenbrink, Tobias Mielke, Tom Parke, Daniel Evans, Franz Koenig
Summary: In recent years, the popularity of platform trials has increased, but there are still many design-related questions that need further exploration. Existing software packages often target single design elements and lack extensive design flexibility. Collaborative efforts are needed to create software that fully utilizes the flexibility of platform trials.
Review
Medicine, General & Internal
Nurulamin M. Noor, Sharon B. Love, Talia Isaacs, Richard Kaplan, Mahesh K. B. Parmar, Matthew R. Sydes
Summary: Historically, late-phase trials have typically used standard two-arm designs, but there has been an increasing trend in late-phase MAMS platform trials since 2001, with acceleration due to the impact of COVID-19. The majority of current MAMS platforms target either infectious diseases (52%) or cancers (29%), and all identified trials focus on treatment interventions. Medications are the main focus of evaluation in 89% of the MAMS platforms, with 45% including repurposed medications as comparison arms. This study highlights the growing prevalence of MAMS platform trials in late-phase settings and their potential for various disease areas.
Article
Oncology
J. Mulder, S. Teerenstra, P. B. van Hennik, V. Stoyanova-Beninska, E. E. Voest, A. de Boer
Summary: This study aims to provide details on the contextualization of trial results and evaluate the magnitude of benefit of medicinal products approved based on single-arm trials. The results show that the clinical relevance of treatment effects in single-arm trials depends on the effect size and context.
Article
Urology & Nephrology
Nicholas D. James, Wenyu Liu, Sarah Pirrie, Baljit Kaur, Carey Hendron, Daniel Ford, Anjali Zarkar, Richard Viney, Elizabeth Southgate, Amisha Desai, Syed A. Hussain
Summary: This study aimed to assess the feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle-invasive bladder cancer. The results demonstrated that this treatment approach is feasible and safe, and further clinical evaluation of cetuximab in this setting is warranted.
Article
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhofer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Summary: This study evaluated the efficacy and safety of pembrolizumab plus olaparib in previously treated patients with metastatic castration-resistant prostate cancer. The results demonstrated antitumor activity and expected safety of this combination therapy in patients.
Article
Oncology
Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach III, David Dearnaley, Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall, Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle, Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, Amar U. Kishan
Summary: The sequencing of androgen-deprivation therapy (ADT) and radiotherapy (RT) may affect the outcome of prostate cancer depending on the size of the RT field. A study found that the sequencing of ADT has a significant impact on clinical outcomes for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Emma Scott, Kirsty Hodgson, Beatriz Calle, Helen Turner, Kathleen Cheung, Abel Bermudez, Fernando Jose Garcia Marques, Hayley Pye, Edward Christopher Yo, Khirul Islam, Htoo Zarni Oo, Urszula L. McClurg, Laura Wilson, Huw Thomas, Fiona M. Frame, Margarita Orozco-Moreno, Kayla Bastian, Hector M. Arredondo, Chloe Roustan, Melissa Anne Gray, Lois Kelly, Aaron Tolson, Ellie Mellor, Gerald Hysenaj, Emily Archer Goode, Rebecca Garnham, Adam Duxfield, Susan Heavey, Urszula Stopka-Farooqui, Aiman Haider, Alex Freeman, Saurabh Singh, Edward W. Johnston, Shonit Punwani, Bridget Knight, Paul McCullagh, John McGrath, Malcolm Crundwell, Lorna Harries, Denisa Bogdan, Daniel Westaby, Gemma Fowler, Penny Flohr, Wei Yuan, Adam Sharp, Johann de Bono, Norman J. Maitland, Simon Wisnovsky, Carolyn R. Bertozzi, Rakesh Heer, Ramon Hurtado Guerrero, Mads Daugaard, Janne Leivo, Hayley Whitaker, Sharon Pitteri, Ning Wang, David J. Elliott, Benjamin Schumann, Jennifer Munkley
Summary: Prostate cancer is the leading cancer among men, causing over 350,000 deaths worldwide annually. This study reveals that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue and can be used as a biomarker to diagnose the disease with higher accuracy than the traditional PSA test. Additionally, GALNT7 is found to play a role in promoting prostate tumor growth and is associated with cell cycle and immune signaling pathways. Overall, this study highlights the importance of GALNT7-mediated O-glycosylation in prostate cancer progression.
Article
Oncology
Nicolo Bancaro, Bianca Cali, Martina Troiani, Angela Rita Elia, Rydell Alvarez Arzola, Giuseppe Attanasio, Ping Lai, Mateus Crespo, Bora Gurel, Rita Pereira, Christina Guo, Simone Mosole, Daniela Brina, Mariantonietta D'Ambrosio, Emiliano Pasquini, Clarissa Spataro, Elena Zagato, Andrea Rinaldi, Mattia Pedotti, Simona Di Lascio, Francesco Meani, Monica Montopoli, Matteo Ferrari, Andrea Gallina, Luca Varani, Ricardo Pereira Mestre, Marco Bolis, Silke Gillessen Sommer, Johann de Bono, Arianna Calcinotto, Andrea Alimonti
Summary: Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. We have identified a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment. These senescent-like neutrophils express TREM2 and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils.
Article
Medicine, Research & Experimental
Archie Macnair, Matthew Nankivell, Macey L. Murray, Stuart D. Rosen, Sally Appleyard, Matthew R. Sydes, Sylvia Forcat, Andrew Welland, Noel W. Clarke, Stephen Mangar, Howard Kynaston, Roger Kockelbergh, Abdulla Al-Hasso, John Deighan, John Marshall, Mahesh Parmar, Ruth E. Langley, Duncan C. Gilbert
Summary: This study compared cardiovascular data from a clinical trial database with two routinely-collected healthcare systems data resources. The results showed that the concordance between the three datasets was lower than anticipated, and the routinely-collected healthcare systems data could not directly replace current clinical trial practices.
CONTEMPORARY CLINICAL TRIALS
(2023)
Article
Oncology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander, Andrew Kightley, Jeffry Evans, Shing Lee, Alun Bedding, Sally Hopewell, Khadija Rantell, Rong Liu, An-Wen Chan, Johann De Bono, Christina Yap
Summary: The DEFINE study aims to improve the transparency, completeness, reproducibility, and interpretation of EPDF trial protocols (SPIRIT-DEFINE) and their reports (CONSORT-DEFINE). An extensive review of published trials and consultation with international experts will be conducted to refine the guidelines. The final version of the guidelines will be determined through a modified Delphi process and an international consensus meeting.
Article
Oncology
Caroline M. Moore, Lauren E. King, John Withington, Mahul B. Amin, Mark Andrews, Erik Briers, Ronald C. Chen, Francis I. Chinegwundoh, Matthew R. Cooperberg, Jane Crowe, Antonio Finelli, Margaret I. Fitch, Mark Frydenberg, Francesco Giganti, Masoom A. Haider, John Freeman, Joseph Gallo, Stephen Gibbs, Anthony Henry, Nicholas James, Netty Kinsella, Thomas B. L. Lam, Mark Lichty, Stacy Loeb, Brandon A. Mahal, Ken Mastris, Anita V. Mitra, Samuel W. D. Merriel, Theodorus van der Kwast, Mieke Van Hemelrijck, Nynikka R. Palmer, Catherine C. Paterson, Monique J. Roobol, Phillip Segal, James A. Schraidt, Camille E. Short, M. Minhaj Siddiqui, Clare M. C. Tempany, Arnaud Villers, Howard Wolinsky, Steven MacLennan
Summary: This study explores the best practices and research priorities in active surveillance (AS) for prostate cancer. The study reveals that best practices include the use of high-quality MRI to avoid digital rectal examination and repeat biopsies, and the preference for MRI over immediate active treatment for assessing changes in the disease. The highest research priority is the development of a dynamic, risk-adjusted surveillance approach.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Medicine, General & Internal
Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Summary: This study aims to develop guidelines for early phase dose-finding trials through reviewing published trial reports and conducting a Delphi process. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines were developed, and a lay summary toolkit was created through patient and public involvement.
Article
Oncology
Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J. Weir
Summary: The CONSORT-DEFINE guidance provides comprehensive reporting guidelines for early phase dose-finding trials, aiming to improve the quality of reporting and facilitate result interpretation.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J. Weir, An-Wen Chan, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Melanie Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P. Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Johann de Bono
Summary: SPIRIT 2013 provides guidance for clinical trial protocol writing but doesn't cover early phase dose-finding trials adequately. The DEFINE statement is a new guideline that includes recommendations for essential items in the protocols of these trials.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Oncology
Daniela Brina, Adele Ponzoni, Martina Troiani, Bianca Cali, Emiliano Pasquini, Giuseppe Attanasio, Simone Mosole, Michela Mirenda, Mariantonietta D'Ambrosio, Manuel Colucci, Ilaria Guccini, Ajinkya Revandkar, Abdullah Alajati, Toma Tebaldi, Deborah Donzel, Fabio Lauria, Nahjme Parhizgari, Aurora Valdata, Martino Maddalena, Arianna Calcinotto, Marco Bolis, Andrea Rinaldi, Simon Barry, Jan Hendrik Rueschoff, Marianna Sabbadin, Semini Sumanasuriya, Mateus Crespo, Adam Sharp, Wei Yuan, Mathew Grinu, Alexandra Boyle, Cynthia Miller, Lloyd Trotman, Nicolas Delaleu, Matteo Fassan, Holger Moch, Gabriella Viero, Johann de Bono, Andrea Alimonti
Summary: In prostate cancer, the secretome is rewired at the translational level to recruit MDSCs, with Hgf, Spp1, and Bgn identified as key regulators. By inhibiting the MNK/eIF4E and AKT pathways, this study provides a therapeutic strategy that combines translation inhibition with immunotherapy to restore immune surveillance in prostate cancer.